Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced the initiation of a Phase 1 clinical trial for its  ZYN002 cannabidiol (CBD) gel for the treatment of refractory epilepsy, fragile X syndrome and osteoarthritis.
As quoted in the press release:

The “Single Rising Dose Study in Normal Subjects and Patients with Epilepsy” study will evaluate the pharmacokinetic profile and tolerability of ZYN002 in 32 healthy volunteers and then in 12 patients with epilepsy. The first group of healthy volunteers was dosed today in Australia. Results are expected in the first half of 2016.


About ZYN002 CBD gel:

Zynerba’s ZYN002 CBD Gel is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. ZYN002 is a clear, odorless, permeation-enhanced gel that is designed to provide consistent, controlled drug delivery transdermally with convenient once- or twice-daily dosing. Transdermal therapeutics are absorbed through the skin directly into the systemic circulation, avoiding first-pass liver metabolism and potentially enabling lower dosage levels of active pharmaceutical ingredients and rapid and reliable absorption with high bioavailability. In addition, transdermal delivery avoids the gastrointestinal tract and potential stomach acid degradation of CBD into THC, as demonstrated in a Zynerba in vitro study, which may lead to increased psychoactive effects.

Armando Anido, chairman and CEO of Zynerba, commented:

The initiation of the ZYN002 CBD Gel Phase 1 trial is an important development milestone for Zynerba. We believe our novel, highly innovative and proprietary transdermal gel may offer unique advantages by delivering drug through the skin and into the bloodstream. Transdermal delivery of CBD not only avoids first-pass metabolism but it also avoids potential degradation of CBD into THC in the stomach and the associated increased psychoactive effects of THC.  ZYN002 CBD gel presents significant promise for large unmet patient populations.

Click here to read the full Zynerba Pharmaceuticals (NASDAQ:ZYNE) press release.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.

The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.

Keep reading... Show less

A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.

Meanwhile, a cannabis retail operator elected to celebrate 420 by auctioning a cannabis-themed digital art piece using blockchain technology.

Keep reading... Show less

Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.

Keep reading... Show less

Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola

The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).

Keep reading... Show less